 Corporate Presentation to Highlight Companys Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Dec. 2, 2022 PRNewswire -- Genprex, Inc. Genprex or the Company NASDAQ: GNPX , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Companys gene therapies for cancer and diabetes at the following investor conference in December 2022. Event: RHK 2022 Disruptive Growth Conference Conference Dates: Dec. 5-6, 2022 Presentation Date: Tuesday, Dec. 6, 2022 Presentation Time: 2:40 p.m. 